Alte Biosciences

Alte Biosciences is a clinical-stage biotechnology company based in San Diego, California, dedicated to developing next-generation therapies for autoimmune and inflammatory diseases. The company's lead candidate, ALT-101, is a long-acting interleukin-2 (IL-2) mutein designed to selectively stimulate regulatory T cells (Tregs) and restore immune balance. Licensed from Amgen, ALT-101 is currently being evaluated in Phase 1 clinical trials for its potential to treat a variety of immunological conditions. Alte was founded by a highly experienced leadership team with a history of success at companies such as Receptos and Gossamer Bio, and is backed by prominent life science investors including ARCH Venture Partners and venBio Partners.